NCT06793709 A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
| NCT ID | NCT06793709 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Eisai Co., Ltd. |
| Condition | Biliary Tract Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-07-10 |
| Primary Completion | 2032-11-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-07-10 with a primary completion date of 2032-11-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary purpose of this study is to investigate the safety of Tasfygo.
Eligibility Criteria
Inclusion Criteria: 1\. Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy. Exclusion Criteria: Not applicable.
Contact & Investigator
Eisai Inquiry Service
✉ eisai-chiken_hotline@hhc.eisai.co.jpFrequently Asked Questions
Who can join the NCT06793709 clinical trial?
This trial is open to participants of all sexes, studying Biliary Tract Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06793709 currently recruiting?
Yes, NCT06793709 is actively recruiting participants. Contact the research team at eisai-chiken_hotline@hhc.eisai.co.jp for enrollment information.
Where is the NCT06793709 trial being conducted?
This trial is being conducted at Tokyo, Japan.
Who is sponsoring the NCT06793709 clinical trial?
NCT06793709 is sponsored by Eisai Co., Ltd.. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.